SAN CARLOS, Calif. and COPENHAGEN, Denmark, June 16, 2021 (GLOBE NEWSWIRE) — Apexigen, Inc., a clinical-stage biopharmaceutical firm targeted on discovering and creating a brand new technology of antibody therapeutics for oncology, and the Nordic Society of Gynaecological Oncology – Scientific Trial Unit (NSGO-CTU) as we speak introduced an settlement to provoke a collaborative Section 2 scientific research evaluating sotigalimab, Apexigen’s monoclonal antibody concentrating on CD40, together remedy for sufferers with recurrent BRCA wild sort ovarian most cancers. Sotigalimab, Apexigen’s lead immuno-oncology therapeutic candidate, is a probably first-in-class and best-in-class CD40 agonist, with distinctive epitope specificity and Fc receptor engagement for optimum therapeutic impact and tolerability.
“We’re excited to collaborate with the NSGO-CTU and ENGOT, premier organizations with super expertise conducting gynaecological oncology scientific trials,” stated Xiaodong Yang, M.D., Ph.D., President and CEO of Apexigen. “The poor survival in superior ovarian most cancers is due each to late analysis in addition to a scarcity of efficient second-line remedy. Strong preclinical and early scientific knowledge underscore the utility of next-generation immune-modulating therapies, resembling sotigalimab. We imagine combining sotigalimab remedy with chemotherapy or chemotherapy plus radiation exhibits promise in providing new therapeutic choices for sufferers with recurrent BRCA wild sort ovarian most cancers. We’re lucky to have the chance to discover these mixtures with the NSGO-CTU and ENGOT as we proceed to handle the best excellent challenges in oncology.”
“Our objective on the NSGO-CTU and ENGOT is to enhance administration choices in gynaecological most cancers indications by conducting and coordinating scientific trial efforts throughout international locations,” added Mansoor Raza Mirza, M.D., Medical Director of the NSGO-CTU and Chair of ENGOT. “The analysis of sotigalimab, a novel and promising agent, on this Section 2 randomized research is a vital subsequent step to enhance the usual of look after sufferers with ovarian most cancers. We look ahead to working with Apexigen to succeed in our mutual purpose.”
About Sotigalimab (APX005M)
Sotigalimab is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. Sotigalimab targets CD40, a co-stimulatory receptor that’s important for activating each innate and adaptive immune techniques. Binding of sotigalimab to CD40 on antigen presenting cells (i.e., dendritic cells, monocytes and B-cells) initiates a multi-faceted immune response bringing a number of parts of the immune system (e.g., T cells, macrophages) to work in live performance in opposition to most cancers. Sotigalimab is at present in Section 2 scientific improvement for the remedy of cancers resembling esophageal and gastroesophageal junction cancers, melanoma, rectal most cancers and sarcoma in numerous mixtures with immunotherapy, chemotherapy, radiation remedy or a most cancers vaccine. Extra data on scientific trials for sotigalimab could be discovered at www.clinicaltrials.gov.
Apexigen is a clinical-stage biopharmaceutical firm targeted on discovering and creating a brand new technology of antibody therapeutics for oncology, with an emphasis on new immuno-oncology brokers that will harness the affected person’s immune system to fight and eradicate most cancers. Sotigalimab and Apexigen’s different applications had been found utilizing Apexigen’s proprietary APXiMAB™ discovery platform. This platform has enabled Apexigen and its collaboration companions to find and develop high-quality therapeutic antibodies in opposition to a wide range of molecular targets, together with targets which can be tough to drug with typical antibody applied sciences. Seven product or product candidates found utilizing APXiMAB are at present commercially out there or in scientific improvement, both internally by Apexigen or by its licensees. For extra data, please go to www.apexigen.com.
The Nordic Society of Gynaecological Oncology – Scientific Trial Unit is a non-profit group aiming to enhance the follow of prevention, analysis and remedy for gynaecological cancers by supporting analysis and conducting scientific trials throughout international locations.
ENGOT is a platform that ensures that the European spirit and tradition is included into the medical progress in gynaecological oncology, and that every one European sufferers and international locations can take part in an energetic method in scientific analysis and progress. The last word purpose is to convey the most effective remedy to gynaecological most cancers sufferers by way of the most effective science and enabling each affected person in each European nation to entry a scientific trial.
Sr. Vice President, Enterprise Improvement
Mansoor Raza Mirza, MD
Chief Oncologist, Rigshospitalet
Medical Director, NSGO-CTU
+45 3545 9624